Cover Image
市場調查報告書

Alder Biopharmaceuticals Inc.的產品平台分析

Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 276019
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Alder Biopharmaceuticals Inc.的產品平台分析 Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015
出版日期: 2015年10月30日 內容資訊: 英文 32 Pages
簡介

Alder Biopharmaceuticals Inc.是總公司在美國的生物科技企業,進行抗體治療藥的開發、生產、銷售。對象疾病是癌症、免疫疾病、發炎疾病。

本報告提供Alder Biopharmaceuticals Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Alder Biopharmaceuticals Inc. 的基本資料

  • Alder Biopharmaceuticals Inc. 概要
  • 主要資訊
  • 企業資料

Alder Biopharmaceuticals Inc. :R&D概要

  • 主要的治療範圍

Alder Biopharmaceuticals Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Alder Biopharmaceuticals Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Alder Biopharmaceuticals Inc.:藥物簡介

  • ALD-403
  • clazakizumab
  • ALD-806
  • ALD-901
  • Monoclonal Antibody-1 for Undisclosed Indication
  • Monoclonal Antibody-2 for Undisclosed Indication
  • Monoclonal Antibody-3 for Undisclosed Indication
  • Monoclonal Antibody-4 for Undisclosed Indication

Alder Biopharmaceuticals Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alder Biopharmaceuticals Inc. :最新的開發平台資訊

Alder Biopharmaceuticals Inc. :現在暫停中的計劃

Alder Biopharmaceuticals Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07729CDB

Summary

Global Markets Direct's, 'Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2015', provides an overview of the Alder Biopharmaceuticals Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alder Biopharmaceuticals Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alder Biopharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alder Biopharmaceuticals Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alder Biopharmaceuticals Inc.'s pipeline products

Reasons to buy

  • Evaluate Alder Biopharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alder Biopharmaceuticals Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alder Biopharmaceuticals Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alder Biopharmaceuticals Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alder Biopharmaceuticals Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alder Biopharmaceuticals Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alder Biopharmaceuticals Inc. Snapshot
    • Alder Biopharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Alder Biopharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alder Biopharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alder Biopharmaceuticals Inc. - Pipeline Products Glance
    • Alder Biopharmaceuticals Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Alder Biopharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alder Biopharmaceuticals Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Alder Biopharmaceuticals Inc. - Drug Profiles
    • ALD-403
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • clazakizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALD-1613
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-2 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-3 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody-4 for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alder Biopharmaceuticals Inc. - Pipeline Analysis
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Target
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Alder Biopharmaceuticals Inc. - Pipeline Products by Mechanism of Action
  • Alder Biopharmaceuticals Inc. - Recent Pipeline Updates
  • Alder Biopharmaceuticals Inc. - Dormant Projects
  • Alder Biopharmaceuticals Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alder Biopharmaceuticals Inc., Key Information
  • Alder Biopharmaceuticals Inc., Key Facts
  • Alder Biopharmaceuticals Inc. - Pipeline by Indication, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Alder Biopharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Alder Biopharmaceuticals Inc. - Phase III, 2015
  • Alder Biopharmaceuticals Inc. - Phase II, 2015
  • Alder Biopharmaceuticals Inc. - Preclinical, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Target, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Route of Administration, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Molecule Type, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2015
  • Alder Biopharmaceuticals Inc. - Recent Pipeline Updates, 2015
  • Alder Biopharmaceuticals Inc. - Dormant Developmental Projects,2015

List of Figures

  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Indication, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Stage of Development, 2015
  • Alder Biopharmaceuticals Inc. - Monotherapy Products in Pipeline, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Target, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Alder Biopharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top